BioFactura, Inc.

Aurobindo Pharma Limited’s biosimilars subsidiary CuraTeQ Biologics has entered into an exclusive commercialization and manufacturing agreement with BioFactura, Inc. for the US-based firm’s BFI-751

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas To Select Up To Five Targ

Johnson & Johnson has a host of biosimilar rivals on the horizon each wanting a slice of its $9.7bn Stelara (ustekinumab) sales pie and until recently, biosimilars industry analysts had predicted tha

BioFactura is joining forces with Rani Therapeutics Holdings, Inc. to assess BioFactura’s BFI-751 biosimilar Stelara (ustekinumab) candidate with Rani’s RaniPill platform technology, which intends